Keynote speaker:Jacques Banchereau,

Baylor Institute for Immunology Research

Additional talks on immunology of infection, autoimmunity, cancer and

translational research in humans

For free meeting registration, please send an email with your name, position, affiliation andcontact information to: Lynne Omoto lynne.omoto@utoronto.ca. Abstracts for posters in any

area of human immunology can be sent as an attachment with registration email.

1st Annual1st AnnualHuman ImmunologyHuman Immunology

Research DayResearch Day

Wednesday June 10, 2009

8:30am – 5:00pm Colony Grand Ballroom

89 Chestnut StreetToronto

Organized by Katherine Siminovitch

Tania Wattsand the

Department of Immunology University of Toronto poster-lunch

session

Poster illustration credit: Immune system components HANS-ULRICH OSTERWALDER/SCIENCE PHOTO LIBRARY, with permssion.

Sponsored by:

HUMAN IMMUNOLOGY RESEARCH DAY June 10, 2009, 8:30-5:00

Colony Grand Ballroom, 89 Chestnut Street, Toronto

Sponsored by the Department of Immunology, University of Toronto and sanofi pasteur

Goal: to facilitate interactions between basic and clinician scientists and trainees to further the development of Human Immunology as a discipline in Toronto; to set a framework for future interactions. 8-8:30 Coffee available in the poster area/Posters go up on boards Morning session: Infectious disease, Chair: Tania Watts 8:30 Welcome- Michael Ratcliffe, Department of Immunology 8:35 Kevin Kain, University Health Network Severe Infections: Who will die? Why do they die? and What can we do about it? 9:05 Mario Ostrowski, University of Toronto The role of Tim-3 in T cell exhaustion in chronic virus infections 9:35 Tania Watts, University of Toronto Role of 4-1BB and TRAF1 in anti-viral immunity 10:05- 10:30 Break 10:30 Quim Madrenas, University of Western Ontario On superantigens and superbugs: modulation of immunity by the Staphylococcal

cell wall Keynote address: 11-12 Dr. Jacques Banchereau, Director Baylor Institute for Immunology Research Human Immunology: a Fertile Field for Basic and Patient-Oriented Discoveries

12:00 Poster session over lunch Afternoon session: Cancer, Autoimmunity and translational research, Chair Katherine Siminovitch 2:00 Neil Berinstein, University of Toronto Optimizing cancer vaccine development in melanoma 2:30 Li Zhang, University Health Network Anti-tumor effect of ex vivo expanded human DNT cells 3:00 Joan Wither, University Health Network, B cell abnormalities in human lupus 3:30-4 Break 4:00 Katherine Siminovitch, Mt. Sinai hospital, Genetic dissection of autoimmune

disease - the end of the beginning 4:30 Juan Carlos Zuniga Pflücker, Sunnybrook and Women’s Hospital From stem cells to T cells, producing human T-progenitors for immune-

regeneration

Registration (free): Please email Lynne Omoto lynne.omoto@utoronto.ca with your name, position, affiliation and contact information Abstracts submission: Posters focused on the topic of human immunology will be presented during lunch time poster session. Send the abstract as an attachment with your registration. Format: Word document: Title, authors (presenter first), affiliation, 250 word max abstract. Deadline for abstract submission: EXTENDED TO MAY 22nd. Poster boards are 6 feet wide by 3 feet high. We can accommodate 2 per side at 3 feet wide, but for those who have posters from other meetings that are wider, please indicate this when you submit, and we will try to accommodate all.

Sano� Pasteur is interested in partners who will share in our pursuit of innovation and our drive for excellence, while becoming a part of our market success story. We welcome the opportunity to evaluate technologies related to the development and production of human vaccines, both prophylactic and therapeutic, including infectious diseases, cancer and chronic diseases.

Sano� Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes, government bodies, biotechnology companies and contract research organizations. Our col-laborations cover virtually all aspects of vaccine develop-ment, including early-stage research.

Examples of current partnerships and technology invest-ments include: tuberculosis, dengue, malaria, Japanese encephalitis, and colorectal cancer vaccine development; large-scale, cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; vaccine delivery systems; and the production of combina-tion vaccines.

When partnering with sano� pasteur, you will interact with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed suc-cessfully and nurtured for the mutual bene�t of all parties. �is approach utilizes the value-added sano� pasteur alli-

ance management capability, which focuses on the rela-tionship by facilitating open communication, trust, understanding, and clear expectations across the project lifecycle. Combined with the technical competencies of the alliance, this balance provides a well-rounded envi-ronment for your technology to �ourish.

Sano� Pasteur is interested in learning of potential part-nering opportunities in the �eld of human vaccines. Subjects of interest might include (but are not limited to) the following:

New antigens or vaccines for infectious diseases and can-cer, and supporting technologies, such as:• antigen discovery and characterization for infectious

diseases and cancer • immunotherapeutics for chronic non-infectious diseases• carrier proteins and protein-polysaccharide conjuga-

tion methods or alternative technologies

Agents to enhance vaccine immune responses — such as adjuvants and immunomodulators — speci�cally including:• adjuvants, particularly those that drive �1 and �2

immune responses• vaccine vectors intended to enhance or modify

immune responses• characterization, modulation and assay of protective

immune responses• areas of basic immunology applicable to vaccine devel-

opment, such as studies of innate immunity, immune escape mechanisms, and immunoregulation

New routes of vaccine administration and vaccine delivery systems, such as:• new ways to administer vaccines• vaccine vectors suitable for nasal or oral use

Tools for improving vaccine research, development and production, for example:

• animal models of human diseases• development and application of new technologies in

the areas of genomics and proteomics• bioinformatics techniques for data handling and analysis• prokaryotic or eukaryotic cell lines for antigen pro-

duction• fermentor and bioreactor technology• downstream processing and puri�cation processes• preservatives and stabilizers• identi�cation of biological markers for evaluating the

e�cacy of prophylactic or therapeutic interventions for infectious diseases and cancer

• epidemiological studies relevant to the use of vaccines and immunotherapeutics

Sano� Pasteur, the vaccines division of sano�-aventis Group, is seeking partners who will share in the company's pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate e�ectively with a broad array of partners around the world.

We are not only at the forefront of conquering newly targeted diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

Partnership opportunities with Sano� Pasteur

CONTACT DETAILSSano� Pasteur welcomes information

about new partnership opportunities.

Each opportunity is carefully evaluated

and reviewed by our dedicated team.

Please contact:

Je�rey Almond, PhD

Vice President, Discovery and External

Research and Development

Phone +33 4 3737 9453

Je�rey.Almond@sano�pasteur.com

Allan Jarvis, Jr. PhD

Vice President, Corporate Development

Phone +1 570 839 5525

Allan.Jarvis@sano�pasteur.com

Sano� Pasteur is a world leader in improving global human health by discovering, developing, manufacturing, and supplying vaccines for the prevention and treatment of infectious diseases and cancer.

LIC

EN

SIN

G E

XE

CU

TIV

E P

RO

FIL

E